Nissan Chemical Industries Limited

Toudai Tlo, Ltd.

Japan Science and Technology Agency

Junji Kamon

Takashi Kadowaki

Toshimasa Yamauchi

Ryozo Nagai

Tsuneo Watanabe

Keishi Hayashi

Masataka Minami

Miyuki Uni

Koji Toyama

Mariko Nasu

Satoshi Kimura

Yukihiro Shigeta

Masato Horikawa

Yutaka Hirokawa

Hiroshi Nagai

Yusuke Shintani

Kazuya Takeuchi

Megumi Io

Hironori Waki

Motoo Tomita

Kei Nagae

This disclosure relates to novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities. A tricyclic heterocyclic compound represented by the formula (I), wherein the rings Aand B, X, Y, R, R, R, L, L, Land nare as defined in the specification. 

Substituted pyrrolo[3',2&#x2032;:5,6]pyrido[4,3-d]pyrimidines and JAK inhibitors comprising the same

Novel tricyclic pyrimidine compounds and tricyclic pyridine compounds having JAK inhibitory activities are provided. A tricyclic heterocyclic compound represented by the formula (I): wherein the rings Aand B, X, Y, R, R, R, LL, Land nare as defined in the description. 

Substituted pyrrolo[2,3-h][1,6]naphthyridines and compositions thereof as JAK inhibitors

Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases. 

Pyridazinone compounds and P2X7 receptor inhibitors

The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability.

Adiponectin receptor and gene encoding the same

The invention provides an insulin resistance improving agent and a therapeutic agent for type 2 diabetes, which contain a C-terminal globular domain of adiponectin, adiponectin, or a gene for the domain or adiponectin. The invention also provides a method for improving insulin resistance and treating type 2 diabetes by administering the aforementioned agent(s).

Insulin resistance improving agents

Growing community of inventors

Saitama, Japan

Junji Kamon